|
|
||||||||
Original Research |
1 Department of Radiology, Massachusetts General Hospital and Harvard Medical
School, Boston, MA 02114.
2 Cardiac MR–PET-CT Program, Massachusetts General Hospital and Harvard
Medical School, Boston, MA 02114.
3 Present address: Department of Radiology, St. Vincent's University Hospital,
Elm Park, Dublin 4, Ireland.
4 Division of Cardiology, Massachusetts General Hospital and Harvard Medical
School, Boston, MA 02114.
Received November 29, 2006;
accepted after revision May 12, 2007.
Address correspondence to J. D. Dodd.
Abstract
|
|
|---|
MATERIALS AND METHODS. In a retrospective blinded study, nine patients with left ventricular noncompaction and 10 control subjects had cardiac MRI studies evaluated for the severity and extent of left ventricular noncompaction and the amount and degree of trabecular delayed hyperenhancement on a myocardial segment basis (16-segment model). Findings were correlated with parameters of clinical stage of disease.
RESULTS. Fifty-seven (39%) myocardial segments showed left ventricular noncompaction whereas 22 (17%) showed trabecular delayed hyperenhancement. Significant differences among clinical severity groups were noted in the severity and extent of left ventricular noncompaction at the mid (p < 0.05 and p < 0.005, respectively) and apical levels (p < 0.003 and p < 0.001, respectively), severity of trabecular delayed hyperenhancement at the mid (p < 0.04) and apical levels (p < 0.02), and amount of trabecular delayed hyperenhancement at the apical level (p < 0.006). The extent of left ventricular noncompaction and the amount and degree of trabecular delayed hyperenhancement correlated significantly with ejection fraction (EF) (r = –0.47, –0.53, –0.53, respectively, p < 0.05). The degree of trabecular delayed hyperenhancement was an independent predictor of EF (R2 = 0.30, p < 0.0001). Significant differences in the severity of trabecular delayed hyperenhancement were detected among patients with mild and those with moderate and severe clinical stage of disease (p < 0.0001).
CONCLUSION. Cardiac MRI shows trabecular delayed hyperenhancement in left ventricular noncompaction. Evaluating the extent and severity of left ventricular noncompaction and trabecular delayed hyperenhancement may improve the ability of the clinician to predict the clinical stage of disease.
Keywords: cardiomyopathy left ventricle abnormality left ventricular noncompaction MRI trabecular delayed hyperenhancement
|
|
|---|
Traditionally, left ventricular noncompaction is diagnosed by echocardiography when the ratio of noncompacted to compacted myocardium is greater than 2. Echocardiography may not visualize the apical region optimally, leading to underestimation of the degree of left ventricular noncompaction [3]. Cardiac MRI provides a comprehensive depiction of cardiac morphology in any imaging plane. Recent cardiac MRI reports suggest a ratio of noncompacted myocardium to compacted myocardium of > 2.3 yields the highest sensitivity (86%) and specificity (99%) in diagnosis [6].
Jenni et al. [7] studied seven patients with left ventricular noncompaction with pathologic correlation (three heart transplant procedures and four post mortem procedures). Histologic analysis revealed ischemic lesions in the thickened endocardium and thickened trabeculae with accompanying fibrosis. Direct imaging of myocardial fibrosis is possible with the use of an inversion recovery prepared T1-weighted gradient-echo sequence and the extracellular fluid tracer gadopentetate dimeglumine [8]. This technique has been termed "delayed hyperenhancement" and shows nonviable tissue as hyperenhanced or bright. Its accurate delineation of fibrous myocardium has been confirmed with several ex vivo techniques (triphenyltetrazolium chloride and histology) [9].
Such techniques are beginning to be used in left ventricular noncompaction. In a recent study by Ivan et al. [10] using delayed hyperenhancement, MRI in three patients with left ventricular noncompaction revealed areas of subendocardial hyperenhancement. Histologic analysis confirmed subendocardial and trabecular fibroelastosis. We have previously published a case report showing trabecular delayed hyperenhancement on cardiac MRI in a patient with severe left ventricular noncompaction [11]. The hypothesis of the current study was that cardiac MRI may detect trabecular delayed hyperenhancement in a series of patients with left ventricular noncompaction and that the amount and degree of trabecular delayed hyperenhancement might be useful in quantifying the clinical stage of disease. The aims of our study were to quantitatively assess the extent and severity of left ventricular noncompaction using the cardiac segmental anatomy recommended by the American Heart Association [12], quantitatively assess the amount and degree of trabecular delayed hyperenhancement, and evaluate the relationship between left ventricular noncompaction and trabecular delayed hyperenhancement with parameters of the clinical stage of disease.
|
|
|---|
In the current study, shortness of breath was defined according to the New
York Heart Association (NYHA) functional classification
[14]. All patients underwent
echocardiography; left ventricular EF < 55% was regarded as abnormal. We
stratified patients as having a mild stage of disease if they had no or
minimal dyspnea (NYHA
I), normal EF < 55%, and no history of
arrhythmias or thromboembolism; a moderate stage of disease if they had
dyspnea (NYHA 0 or I), abnormal EF < 55% but no evidence of arrhythmias or
thromboembolism; and a severe stage of disease if they had dyspnea (NYHA
I), abnormal EF < 55, and Holter monitor evidence of arrhythmia such as
atrial fibrillation or ventricular tachycardia
[5,
13].
MR Imaging Protocol
All subjects were examined on a 1.5-T magnet (Signa CV/i, GE Healthcare)
using an eight-element phased-array cardiac coil for signal reception. Left
ventricular function was obtained with cine images using a steady-state free
precession (SSFP) technique (TR/TE, 3.5/1.4; matrix, 192 x 192; field of
view, 34 x 34 cm; slice thickness, 8 mm) obtained in two-chamber,
four-chamber, and short-axis planes. In addition, in six patients SSFP radial
long-axis views were obtained with the axis placed in the center of the left
ventricular cavity at the mid level and 12–16 slices acquired with
imaging parameters similar to those of the preceding cine sequences.
After baseline imaging, a bolus injection of 0.2 mmol/kg of gadopentetate dimeglumine was administered using an infusion pump at 3 mL/s followed by a 20-mL saline flush. Between 10 and 12 minutes later, delayed hyperenhancement MRI was performed using an inversion recovery prepared gated fast gradient-echo pulse sequence [15]. We acquired multiple sequences with varying inversion time (TI) values and then selected the images with the most appropriate TI. Delayed hyperenhancement images were acquired to optimally show normal myocardium and trabeculae (dark) and regions of delayed hyperenhancement within the myocardium and trabeculae (bright) with proper selection of the TI. Imaging parameters were as follows: 7.1/3.1; matrix, 256 x 192; flip angle, 20°; inversion pulse, 180°; and TI between 150 and 300 milliseconds.
Analysis for Left Ventricular Noncompaction
A cardiac MRI fellowship-trained cardiac radiologist interpreted the images
blinded to the diagnosis and clinical severity in all cases. For the purposes
of this study, the extent of left ventricular noncompaction was taken to
indicate the number of cardiac segments showing left ventricular
noncompaction, and the severity of left ventricular noncompaction was taken to
indicate the ratio of noncompacted to compacted myocardium for a given
myocardial segment. Segmental analysis was evaluated using a standard
17-segment cardiac model as defined by the American Heart Association/American
College of Cardiology (AHA/ACC) for standardized myocardial segmentation
[12]. The apex (segment 17)
was excluded from analysis because it is normally thin and may lead to
false-positive interpretations.
Cine short-axis images for calculation of ejection fraction (EF), end-diastolic volume (EDV), end-systolic volume (ESV), and myocardial mass were evaluated using Simpson's method (MassPlus, Medis, Inc.). Ventricular wall motion abnormalities were defined as normal, mild to moderate hypokinesia, severe hypokinesia, akinesia, or dyskinesia by wall thickening > 30%, 10–29%, < 10%, absent, or no appreciable wall thickening with systolic movement away from the center of the left ventricular segments, respectively [16]. Regional wall motion was scored on a 5-point system: 1 = normal, 2 = mild to moderate hypokinesia, 3 = severe hypokinesia, 4 = akinesia, 5 = dyskinesia) [17]. Distribution of noncompacted to compacted myocardium was quantitatively analyzed by measuring the thickness in millimeters of noncompacted and compacted myocardium in all 16 segments using the acquired cine SSFP sequences. Noncompaction was defined as a ratio of noncompacted to compacted myocardium > 2.3 at end-diastole [6].
Analysis of Trabecular Delayed Hyperenhancement
For the purposes of this study, the amount of trabecular delayed
hyperenhancement indicated the number of cardiac segments exhibiting
trabecular delayed hyperenhancement. The degree of trabecular hyperenhancement
was measured by placing a region of interest (ROI) in the trabeculae and a
second ROI in the middle myocardium of the corresponding myocardial segment at
the same ventricular level. This was performed for each of the 16 segments,
and the ratio of trabecular to myocardial signal was calculated. We defined
trabecular delayed hyperenhancement as present when the ratio of trabecular to
corresponding myocardial signal intensity was
3.
Statistical Analysis
All data are presented as mean ± SD. Data were analyzed per
myocardial segment. Comparison among multiple groups was performed with
Kruskal-Wallis analysis of variance. To compare individual groups at each
ventricular level, the Scheffe post hoc test was used. Univariate correlations
were performed with the Spearman's rank correlation test. Stepwise multiple
regression analysis with EF as the dependent variable and age, sex, extent and
severity of left ventricular noncompaction, and amount and degree of
trabecular delayed hyperenhancement as independent variables was used to
evaluate the relationship among left ventricular dysfunction, left ventricular
noncompaction, and trabecular delayed hyperenhancement. A p value
< 0.05 was considered statistically significant.
|
|
|
|
|
|---|
|
Extent and Severity of Left Ventricular Noncompaction
For severity of left ventricular noncompaction there were statistically
significant differences in the anterior, anterolateral, and inferolateral
segments (Kruskal-Wallis; p < 0.02, p <0.03, and
p < 0.01, respectively) among all clinical stage groups at the mid
level and for all segments at the apical level (p < 0.004)
(Fig. 2). For extent of left
ventricular noncompaction, there were statistically significant differences in
the anterior, anterolateral, inferolateral, and inferior segments (p
< 0.002, p < 0.01, p < 0.02, and p <
0.008, respectively) among all clinical stage groups at the mid level and for
all segments at the apical level (p < 0.001)
(Fig. 3).
|
|
|
|
Intergroup Comparison Among Clinical Stages of Disease for Left Ventricular Noncompaction and Trabecular Delayed Enhancement
For extent of left ventricular noncompaction, at the basal ventricular
level, no significant differences were found among clinical stage groups; at
the midventricular level, significant differences were found among the severe
clinical stage group and all other clinical stage groups; at the apical
ventricular level, no significant differences were found among any clinical
stage groups. For severity of left ventricular noncompaction, at the basal
ventricular level, significant differences were found among the mild and
severe clinical stage groups; at the midventricular level, significant
differences were found among the severe clinical stage group and all other
clinical stage groups; at the apical ventricular level, no significant
differences were found among any clinical groups with left ventricular
noncompaction.
For degree of trabecular delayed hyperenhancement, at the basal ventricular level, significant differences were found between the severe clinical stage group and all other clinical stage groups; at the midventricular level, significant differences were found among the control and mild stage groups compared with the moderate and severe stage groups. At the apical level, no significant differences were found among clinical stage groups. For amount of trabecular delayed hyperenhancement, at the basal ventricular level, significant differences were found between the severe clinical stage group and all other clinical stage groups; at the midventricular level, significant differences were found among the severe clinical group and the control and mild clinical stage groups; no significant difference was detected among the moderate and severe clinical stage groups; at the apical ventricular level, significant differences were found among the moderate and severe clinical stage groups and all other clinical stage groups.
|
|
|
|
|
|---|
Several ventricular levels showed abnormalities in the amount and degree of trabecular delayed hyperenhancement but not in the extent or severity of left ventricular noncompaction. For example, for the degree of trabecular delayed hyperenhancement at the basal ventricular level, significant differences were found among the severe clinical stage group and any of the other clinical stage groups, whereas no differences in the extent of left ventricular noncompaction were found among any of the clinical groups. For the amount of trabecular delayed hyperenhancement at the apical ventricular level, significant differences were found among the moderate and severe clinical stage groups and all other clinical stage groups compared with no significant differences in extent or severity of left ventricular noncompaction.
Furthermore, stepwise linear regression analysis revealed the amount of trabecular delayed hyperenhancement to be the only independent predictor of EF (R2 = 0.30, p < 0.05). The most likely explanation for this finding is that several myocardial segments showed trabecular delayed hyperenhancement with a normal ratio of compacted to noncompacted myocardium, which was unexpected. This was found mostly in patients with clinically severe stages of disease and suggests that in patients with left ventricular noncompaction, even in segments that do not meet the morphologic criteria for left ventricular noncompaction, ischemic trabecular foci may coexist.
It has been suggested that increasing severity of trabecular fibrosis may affect inotropic function [5], and our results would also support this concept. Delayed enhanced cardiac MRI was used by Ivan et al. [10] in a study of three patients with left ventricular noncompaction who underwent heart transplantation. Interestingly, delayed hyperenhancement was detected in a subendocardial distribution in two of three patients. Histologic examination revealed spongy myocardium with focal fibroelastosis, fibrointimal proliferation, and thickening of the endocardial lining. That distribution differs from our findings in which delayed hyperenhancement had a characteristic dotlike appearance within the trabeculae of noncompacted myocardium. The patients in the study by Ivan et al. may have had more severe disease than those in our study (two patients were awaiting transplantation and required bridging with a biventricular assist device). It may be that fibroelastosis progresses from trabecular to subendocardial endocardium with progressively severe disease. It is also possible that technical differences in our study, such as higher matrix resolution and use of double-dose gadolinium, may have resulted in better depiction of fibrosis within the trabeculae, although we cannot confirm this because few MRI technical parameters were included in the study by Ivan et al. Such differences in enhancement pattern highlight the poorly understood pathophysiologic mechanisms leading to left ventricular noncompaction and its clinical manifestations.
That the extent and severity of left ventricular noncompaction correlated with global left ventricular dysfunction corroborates previous echocardiographic studies of left ventricular noncompaction [4, 7]. A distinct advantage of MRI is the ability to depict fibrosis with contrast-enhanced delayed imaging. In our study, the extent and severity of left ventricular noncompaction did not correlate as strongly with EF as did the amount and degree of trabecular delayed hyperenhancement. Jenni et al. [7] showed ischemic lesions and fibrosis within the thickened trabeculae of the noncompacted myocardium in seven patients with left ventricular noncompaction. Histologically, the amount of such fibrosis varied considerably, supporting our observation that trabecular delayed hyperenhancement was distributed heterogeneously through the noncompacted myocardial layer.
In the absence of MRI delayed hyperenhancement sequences, therefore, the degree of fibrotic and possibly dysfunctional cardiac segments may be underestimated on routine cardiac MRI protocols because certain segments with a normal ratio of compacted to noncompacted myocardium may contain trabecular fibrosis. Thus, depiction of trabecular delayed hyperenhancement appears to improve the correlation between MRI and progressive clinical stages of disease in comparison with routine MRI protocols.
Quantifying the severity and extent of left ventricular noncompaction was also important. We found the greatest difference among patients with different clinical stages of disease was at the midventricular level. Evidence of left ventricular noncompaction at the midventricular level suggests the presence of more severe clinical disease. Evidence of left ventricular noncompaction at the apical level is not a useful discriminator because all patients in our series, even those with a mild clinical stage of disease, showed apical left ventricular noncompaction.
Six patients had radial long-axis SSFP sequences of the left ventricle in addition to traditional cardiac MRI two-chamber, four-chamber, and short-axis views. Imaging techniques primarily using short-axis planes to diagnose left ventricular noncompaction can potentially overestimate the extent and severity of left ventricular noncompaction, particularly at the apical region, which is also the most commonly affected [6]. For example, in the study by Ivan et al. [10], 2D echocardiography failed to diagnose left ventricular noncompaction in all three patients. An advantage of cardiac MRI is its ability to prescribe imaging planes in any obliquity. Prescribing radial long-axis projections ensures that each slice passes through the center of the ventricle, minimizing the potential to overestimate the ratio of compacted to noncompacted myocardium. Although a formal comparison of different imaging planes was not the primary focus of this study, nevertheless, we found radial long-axis projections most useful and suggest these to be the optimal imaging planes for cardiac MRI evaluation of left ventricular noncompaction.
A limitation of our study was the small number of patients. Left
ventricular noncompaction is a rare cardiomyopathy that has yet to be
comprehensively classified
[18]. A related point is the
small number of myocardial segments with severe regional wall motion
abnormalities. Segments exhibiting dyskinesis lacked trabecular delayed
hyperenhancement, which does not support our hypothesis. However, only five
out of a potential 128 segments showed dyskinesis. Cardiac MRI studies with
larger numbers of patients with left ventricular noncompaction are needed to
elucidate further the relationship between left ventricular noncompaction and
ventricular dysfunction. A very mild increased signal related to residual
contrast material within the left ventricular cavity may be seen in healthy
subjects and should not be confused with the marked dotlike pattern of
trabecular delayed hyperenhancement in left ventricular noncompaction. We used
a ratio for including a segment as showing trabecular delayed hyperenhancement
of
3, which was arbitrarily chosen; this should not invalidate our
findings because the control group had the same criteria applied. However, it
would be of interest to validate this ratio in a larger group of patients with
left ventricular noncompaction and to evaluate it as a differentiating feature
from other types of cardiomyopathies in future studies.
In conclusion, cardiac MRI delayed hyperenhancement sequences can show trabecular delayed hyperenhancement. Some trabeculae show delayed hyperenhancement despite having a normal compacted-to-noncompacted myocardial ratio, suggesting that left ventricular noncompaction may be a more diffuse disease process than previously suspected. The use of delayed hyperenhancement sequences improves the correlation between cardiac MRI and the parameters of clinical stage of disease.
|
|
|---|
This article has been cited by other articles:
![]() |
G. Fazio, C. Visconti, L. D'Angelo, G. Novo, S. Novo, and and colleagues Delayed MRI Hyperenhancement in Noncompaction: Sign of Fibrosis Correlated with Clinical Severity Am. J. Roentgenol., April 1, 2008; 190(4): W273 - W273. [Full Text] [PDF] |
||||
![]() |
J. D. Dodd and R. C. Cury Reply Am. J. Roentgenol., April 1, 2008; 190(4): W274 - W274. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |